Abstract
Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity. We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a coactivator for critical transcription factors including the androgen receptor. This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain. Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1465-1469 |
Number of pages | 5 |
Journal | Science |
Volume | 338 |
Issue number | 6113 |
DOIs | |
State | Published - Dec 14 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- General